Personal
Become a Client
Karyopharm Therapeutics Inc (USD)
KPTI
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range8.12 | 8.95
52-Wk Range- | -
Last Close8.19
Mkt Cap (m)615.01
Dividend yield-
ISINUS48576U1060
Volume1,263,502.00
Exchange VenueNAS

Company Profile

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.

Key Information
Price/Earning-
Price/Book0.00
Price/Sales5.34
P/CF-
Rev Growth (3 year avg)306.85
EPS Growth (3 year avg)-
Operating Margin % -159.00
Net Margin %-181.59
Return on Equity-391.29
Debt/Equity2.59

Documents

Prospectus
en 05/05/2020
Annual Report
en 31/12/2020

Please refer to the below issuer website for further documents.

http://www.karyopharm.com

Financials

Income Statement
USD201520162017201820192020
Revenue (m)0.250.151.6130.3440.89108.09
Operating Income (m)-119.08-110.73-130.54-179.88-189.28-171.85
Net Income (m)-118.18-109.58-128.98-178.41-199.59-196.27
Basic EPS-3.32-2.92-2.81-3.14-3.22-2.72
Avg. Diluted Shares Outstanding (m)35.6237.5245.9056.8061.9672.04
Balance Sheet
USD201520162017201820192020
Current Assets (m)177.60131.64148.42334.61278.57276.53
Non Current Assets (m)37.8448.7531.876.5816.3936.52
Total Assets (m)215.44180.39180.29341.19294.96313.05
Current Liabilities (m)15.1316.4849.4746.9046.3560.20
Total Liabilities (m)------
Total Equity (m)198.37162.24129.46183.1749.7750.55
Cash Flows
USD201520162017201820192020
Operating Cash Flows (m)-94.03-84.39-73.72-159.12-190.82-160.23
Capital Expenditure (m)-1.42-0.07-0.06-2.36-0.21-0.15
Figures are quoted in USD unless stated otherwise
0.61 (7.45%)
$
8.80
Last Price